Guidelines for Managing Ductal Carcinoma In Situ

publication Evidence: moderate

Author Information

Author(s): Brackstone Muriel, Durocher-Allen Lisa, Califaretti Nadia, Eisen Andrea, Knowles Sarah, Salim Abeer, Plexman Taude, Koch C. Anne

Primary Institution: Ontario Health (Cancer Care Ontario)

What are the most effective therapy options for Ductal Carcinoma In Situ (DCIS) patients?

The guideline provides valuable insights for clinical decision-making regarding the management of DCIS.

The guideline includes ten recommendations and 27 qualifying statements.
Recommendations were developed based on systematic reviews and expert consensus.
The guideline emphasizes the importance of patient preferences in treatment decisions.
Evidence suggests that a margin width of at least 2 mm minimizes the risk of local recurrence.
Adjuvant radiation therapy is recommended for women with DCIS who have undergone breast-conserving surgery with negative margins.
Endocrine therapy options should be discussed for women with estrogen receptor-positive DCIS.
Active surveillance is an area of ongoing investigation for certain patients.
The guideline aims to improve the management of patients with DCIS.

This guideline helps doctors decide the best treatments for patients with a type of breast cancer called DCIS.

The guideline was developed through systematic reviews and internal and external reviews by experts.

Potential biases may arise from the consensus process and the selection of studies included.

The guideline does not cover diagnosis, staging, follow-up, quality of life, or patient education.

The recommendations apply to women with DCIS, including those with microinvasion.

Access the complete publication on the publisher's website